Immunotherapy combo shows promise in ovarian cancer trial
NCT ID NCT03249142
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two immunotherapy drugs, durvalumab and tremelimumab, given with chemotherapy before and after surgery for advanced ovarian cancer. The goal was to see if this combination is safe and feasible. About 69 women with stage IIIC to IV ovarian cancer took part. The results help guide future research on using immunotherapy earlier in treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and tremelimumab (immune checkpoint inhibitors) plus chemotherapy
What this could lead to
If successful, this could point toward a new treatment option for advanced ovarian cancer by combining immunotherapy with standard chemotherapy before surgery.
What could go wrong
This is an early feasibility study with only 69 participants, so results may not apply to all patients. Immune-related side effects are possible and could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Eugene Marquis
Rennes, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Groupe confluent
Nantes, 44202, France
-
Gustave Roussy
Villejuif, France
-
HEGP
Paris, France
-
Hôpital Cochin
Paris, France
-
ICM Val d'Aurelle
Montpellier, France
-
Institut Bergonié
Bordeaux, France
-
Institut René Godinot
Reims, France
-
Institut Ste Catherine
Avignon, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France